Chang-Ming Huang, Prof.
10
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Integrating Multi-Omics Data for Enhanced Prognosis Prediction in Gastric Cancer Post-Neoadjuvant Therapy
Role: lead
Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT
Role: lead
ML Decision Model for G-NEC Adjuvant Therapy
Role: lead
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.
Role: lead
Comparison of Long-term Outcomes Between Upfront Surgery and Neoadjuvant Therapy Followed by Surgery in Patients with Node-Negative Gastric Cancer
Role: lead
Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy
Role: lead
Interpretable Machine Learning Models for Prognosis in Gastric Cancer Patients
Role: lead
Prediction Model for Advanced Gastric Cancer in Elderly
Role: lead
Model for Prognosis of Elderly Gastric Cancer Patients
Role: lead
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
Role: lead
All 10 trials loaded